Epithalon
Also known as: Epitalon, Epithalone, AGAG
Key Facts: Epithalon
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Primarily Russian research. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
- Administration
- Subcutaneous or intramuscular injection
- Typical Dose
- 5-10 mg daily for 10-20 days
- Frequency
- Once daily in cycles
- Duration
- 10-20 day cycles
Mechanism of Action
Epithalon stimulates telomerase production, potentially slowing or reversing telomere shortening. It may also regulate melatonin production by the pineal gland and has been shown to influence gene expression related to aging.
Research Summary
Russian studies show increased telomerase activity and extended lifespan in animal models. Human studies suggest improved sleep, reduced cortisol, and potential immune benefits. Research quality and Western replication remains limited.
Dosing Information
Typical Dosingⓘ
Community experience
5-10 mg daily for 10-20 days
5-20 mg daily
Once daily in cycles
Run in cycles of 10-20 days, then break for months. Targets telomerase activation. Usually done 1-2x per year.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
5-10 mg daily for 10-20 days
Cycles repeated 1-2x per year
Duration
10-20 day cycles
Administration
Subcutaneous or intramuscular injection
Timing & Administration
Best Time to Take
Before bed
Once daily for 10-20 day cycles
Food Recommendation
With or without food
Why This Timing?
Epithalon supports telomere health and melatonin. Evening dosing aligns with natural repair processes during sleep.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Mild headache (transient)
- ●Sleep disturbances
- ●Risk of immunogenicity
- ●Long-term safety not established
References
- https://pubmed.ncbi.nlm.nih.gov/12937682/
- https://pubmed.ncbi.nlm.nih.gov/14501183/
- https://pubmed.ncbi.nlm.nih.gov/40908429/
Research This Peptide Further
Frequently Asked Questions
What does Epithalon do?
A tetrapeptide studied for its effects on telomerase activation and potential anti-aging properties. Based on research by Professor Vladimir Khavinson.
How does Epithalon work?
Epithalon stimulates telomerase production, potentially slowing or reversing telomere shortening. It may also regulate melatonin production by the pineal gland and has been shown to influence gene expression related to aging.
Is Epithalon FDA approved?
No, Epithalon is not currently FDA approved. Current status: Investigational - Primarily Russian research. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
What are the side effects of Epithalon?
Reported side effects include: Generally well-tolerated, Injection site reactions, Mild headache (transient), Sleep disturbances, Risk of immunogenicity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Epithalon?
Community-reported common dose: 5-10 mg daily for 10-20 days (Once daily in cycles). Range: 5-20 mg daily. Administration: Subcutaneous or intramuscular injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Epithalon or used in similar applications.
Thymalin
Clinical TrialsA thymic peptide complex used in Russia for immune enhancement and anti-aging. Part of Professor Khavinson's bioregulator peptide research.
BioregulatorsPinealon
PreclinicalA synthetic tripeptide bioregulator targeting brain tissue. Part of Khavinson's peptide research, designed to support cognitive function and neuroprotection.
BioregulatorsVilon
PreclinicalA synthetic dipeptide bioregulator targeting thymic function. Part of Khavinson's peptide bioregulator research for immune and anti-aging effects.
BioregulatorsCrystagen
PreclinicalA tripeptide bioregulator supporting immune system function. Demonstrates age-associated immunoprotective properties in spleen tissue. Part of the Khavinson synthesized peptide series.
BioregulatorsVentfort
PreclinicalA peptide bioregulator targeting vascular tissue and blood vessels. Derived from blood vessel extracts, it supports healthy vascular function and vessel wall integrity. Part of the Khavinson bioregulator family.
BioregulatorsCartalax
PreclinicalA synthetic tripeptide bioregulator targeting cartilage tissue. Developed for joint health and cartilage regeneration.
BioregulatorsWant updates on Epithalon research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.